Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models
Stock Information for Rafael Holdings Inc. Class B
Loading
Please wait while we load your information from QuoteMedia.